Michael Sarosdy, MD | Authors

MEDICINE SHOPPE 1906

Articles

Commentary (Sarosdy): BCG Immunotherapy for Transitional-Cell Carcinoma in Situ of the Bladder

October 01, 1995

Dr. Lamm's review of bacillus Calmette-Guérin (BCG) in the treatment of carcinoma in situ (CIS) of the bladder reflects one of the largest personal experiences of any investigator worldwide, and he should be congratulated for being one of those most responsible for the improved quality of life of many people due to the widespread use of BCG in bladder cancer. It is clear that BCG therapy allows a majority of patients with CIS to avoid cystectomy, and that it prevents progression to muscle involvement in many high-risk patients with papillary tumors.